New insights in the management of chronic hepatitis B.

Chronic hepatitis B (CHB) remains a global healthcare challenge, complicated by the development of cirrhosis and hepatocellular carcinoma, accounting for approximately 600,000 deaths per year. Hepatitis B is a DNA virus, which utilises a covalently closed circular (ccc) DNA to act as a transcriptional template for the virus. The persistence of cccDNA in the nucleus of infected hepatocytes accounts for HBV chronicity. Quantitative hepatitis B surface antigen (qHBsAg) acts as a surrogate for the level of cccDNA and therefore may provide useful information around treatment response and viral immune control. Current antiviral therapies are limited in their ability to achieve HBsAg loss, which is considered the 'gold-standard' treatment endpoint. This article focuses on the unmet needs in CHB today; a better definition of disease phase, the timing of therapeutic intervention, optimising treatment strategies with current therapies and the development of novel agents; all with HBsAg loss as the therapeutic goal.

[1]  A. Bertoletti,et al.  The immune tolerant phase of chronic HBV infection: new perspectives on an old concept , 2014, Cellular and Molecular Immunology.

[2]  T. Asselah,et al.  HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Bertoletti,et al.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? , 2014, Medical Microbiology and Immunology.

[4]  A. Bertoletti,et al.  Hepatitis B: future curative strategies , 2014, Current opinion in infectious diseases.

[5]  Q. Ning,et al.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). , 2014, Journal of hepatology.

[6]  U. Gill,et al.  Chronic hepatitis B virus in young adults: the need for new approaches to management , 2014, Expert review of anti-infective therapy.

[7]  G. Foster,et al.  Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B , 2014 .

[8]  Y. Liaw,et al.  Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels , 2013, Hepatology.

[9]  J. Pawlotsky,et al.  Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. , 2013, Journal of hepatology.

[10]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[11]  Ding‐Shinn Chen,et al.  Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads , 2013, Hepatology.

[12]  M. Dandri,et al.  Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? , 2013, Journal of hepatology.

[13]  F. Zoulim.  Are novel combination therapies needed for chronic hepatitis B? , 2012, Antiviral research.

[14]  I. Ushiro-Lumb,et al.  Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. , 2012, Gastroenterology.

[15]  P. Marcellin,et al.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients , 2012, Hepatology International.

[16]  H. Janssen,et al.  Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[17]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[18]  M. Manns,et al.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. , 2010, Journal of hepatology.

[19]  G. Gores,et al.  HEPATOLOGY: A home for hepatocellular cancer publications , 2009, Hepatology.

[20]  C. Chu,et al.  Hepatitis B virus infection , 2009, The Lancet.

[21]  S. Yuen,et al.  Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase , 2007, Hepatology.

[22]  S. Hadziyannis,et al.  Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment , 2006, Seminars in liver disease.

[23]  B. McMahon,et al.  [AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. , 2004, Romanian journal of gastroenterology.

[24]  C. Chu,et al.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. , 1983, Gastroenterology.